FrancophonIA/ELRC3.0 huggingface dataset:
English: Because Yargesa is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Yargesa on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Yargesa is a ‘generic medicine'.
Estonian: Yargesa on geneeriline ravim.
English: Why is Yargesa approved?
Estonian: Miks Yargesa heaks kiideti?
English: This is a summary of the European public assessment report (EPAR) for Yargesa.
Estonian: See on ravimi Yargesa Euroopa avaliku hindamisaruande kokkuvõte.
English: As a result, glucosylceramide builds up in different parts of the body, such as the spleen, liver and bones.
Estonian: Selle tulemusel koguneb glükosüültseramiid organismi, näiteks põrna, maksa ja luudesse.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Yargesa has been shown to have comparable quality and to be bioequivalent to Zavesca.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Yargesa võrdväärne kvaliteet ja bioekvivalentsus ravimiga Zavesca.
English: Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Zavesca, and do not need to be repeated for Yargesa.
Estonian: Võrdlusravimiga Zavesca on juba toimunud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Yargesa korrata.
English: It is not intended to provide practical advice on how to use Yargesa.
Estonian: Hindamisaruandes ei anta Yargesa kasutamise praktilisi nõuandeid.
English: Yargesa is available as 100 mg capsules to be taken by mouth.
Estonian: Yargesat turustatakse 100 mg suukaudsete kapslitena.
English: Yargesa is used in patients who cannot receive enzyme-replacement therapy.
Estonian: Yargesat kasutatakse patsientidel, kes ei saa kasutada ensüümasendusravi.
English: Yargesa is a medicine used to treat adults with mild to moderate type-1 Gaucher disease.
Estonian: Yargesa on ravim, mida kasutatakse vähese kuni mõõduka 1. tüüpi Gaucher' tõvega täiskasvanute raviks.
English: For practical information about using Yargesa, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Yargesa kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: By preventing the enzyme from working, miglustat can reduce the production of glucosylceramide in cells, thereby reducing the symptoms of type-1 Gaucher disease.
Estonian: Ensüümi toimet pärssides võib miglustaat vähendada glükosüültseramiidi teket rakkudes, vähendades seega 1. tüüpi Gaucher' tõve sümptomeid.
English: Therefore, the CHMP's view was that, as for Zavesca, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Zavesca korral, ületab ravimi Yargesa kasulikkus sellega kaasnevad riskid.
English: For more information about treatment with Yargesa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Yargesaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Patients with this disease lack an enzyme that breaks down a type of fat called glucosylceramide.
Estonian: Selle haigusega patsientidel puudub ensüüm, mis lagundab glükosüültseramiidi (teatud rasv).
English: How does Yargesa work?
Estonian: Kuidas Yargesa toimib?
English: This enzyme is involved in the first step of the production of glucosylceramide.
Estonian: See ensüüm osaleb glükosüültseramiidi tekke esimesel etapil.
English: A lower dose should be used in patients with reduced kidney function and those who develop diarrhoea.
Estonian: Neeru talitlushäirega patsiendid ja need, kellel tekib kõhulahtisus, peavad kasutama väiksemat annust.
English: The medicine can only be obtained with a prescription and treatment should be supervised by doctors who are experienced in the management of Gaucher disease.
Estonian: Ravi peab algama ja toimuma Gaucher' tõve ravis kogenud arsti järelevalve all.
English: What are the benefits and risks of Yargesa?
Estonian: Milles seisneb Yargesa kasulikkus ja mis riskid ravimiga kaasnevad?
English: The active substance in Yargesa, miglustat, prevents an enzyme called glucosylceramide synthase from working.
Estonian: Yargesa toimeaine miglustaat pärsib ensüümi glükosüültseramiidsüntaasi toimet.
English: How is Yargesa used?
Estonian: Kuidas Yargesat kasutatakse?
English: How has Yargesa been studied?
Estonian: Kuidas Yargesat uuriti?
English: EU number Invented name Strength Pharmaceutical form Route of administration Packaging Content (concentration) Package size EU/1/02/235/001 Monotard
Estonian: EU/1/02/235/001 EU/1/02/235/002 EU/1/02/235/003 EU/1/02/235/004
English: Medicinal Product no longer authorised
Estonian: Ravimpreparaadi nimetus
English: Tavanic is marketed in the following EU Member States: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and United Kingdom.
Estonian: Tavanici turustatakse järgmistes Euroopa Liidu liikmesriikides: Austria, Belgia, Bulgaaria, Eesti, Hispaania, Iirimaa, Itaalia, Kreeka, Küpros, Leedu, Luksemburg, Madalmaad, Malta, Poola, Portugal, Prantsusmaa, Rootsi, Saksamaa, Slovakkia, Sloveenia, Soome, Tšehhi Vabariik, Ungari ja Ühendkuningriik.
English: The European Commission issued a decision on 31 July 2012.
Estonian: Euroopa Komisjon tegi otsuse 31. juulil 2012.
English: What is Tavanic?
Estonian: Mis on Tavanic?
English: Why was Tavanic reviewed?
Estonian: Miks Tavanici andmed uuesti läbi vaadati?
English: The company that markets these medicines is Sanofi.
Estonian: Neid ravimeid turustab ettevõte Sanofi.
English: Tavanic is an antibiotic that belongs to the group ‘fluoroquinolones'.
Estonian: Tavanic on fluorokinoloonide rühma kuuluv antibiootikum.
English: After reviewing the available data supporting the use of the medicine, the CHMP agreed that:
Estonian: Pärast ravimi kasutamist toetavate olemasolevate andmete läbivaatamist märkis inimravimite komitee järgmist:
English: The amended information to doctors and patients is available here for solution for infusion and tablets.
Estonian: Muudetud teave arstidele ja patsientidele on siin: infusioonilahus ja tabletid.
English: The CHMP also harmonised other sections of the SmPC including the addition of a new warning in section 4.4 recommending that an eye specialist should be consulted if vision becomes impaired or any effects on the eyes are experienced.
Estonian: Inimravimite komitee ühtlustas ka teised ravimi omaduste kokkuvõtte lõigud, lisades uue hoiatuse lõiku 4.4, mis soovitab konsulteerida silmaarstiga, kui tekib nägemishäire või ravim mõjub silmadele mis tahes muul viisil.
English: On 24 May 2012 the European Medicines Agency completed a review of Tavanic.
Estonian: 24. mail 2012 lõpetas Euroopa Ravimiamet (EMA) Tavanici kohta tehtud taotluse läbivaatamise.
English: On 11 October 2010, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Tavanic in the EU.
Estonian: 11. oktoobril 2010 tegi Euroopa Komisjon inimravimite komiteele esildise, et ühtlustada Tavanici müügiload Euroopa Liidus.
English: Tavanic is currently used to treat various infections and is available as tablets or solution for infusion.
Estonian: Tavanici kasutatakse praegu mitmesuguste infektsioonide ravis ja seda turustatakse tablettide või infusioonilahusena.
English: In addition, the Committee added new side effects in section 4.8 including ligament rupture, hypoglycaemic coma, benign intracranial hypertension, as well as palpitations and ventricular tachycardia, which may result in cardiac arrest.
Estonian: Peale selle lisas komitee lõiku 4.8 uued kõrvalnähud, sh sidemerebend, hüpoglükeemiline kooma, healoomuline intrakraniaalne hüpertensioon ning ka südamepekslemine ja ventrikulaarne tahhükardia, mis võib põhjustada südameseiskuse.
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.
Estonian: Esitatud andmete hindamise ja komitees toimunud teadusliku arutelu põhjal järeldas inimravimite komitee, et ravimi omaduste kokkuvõtted, märgistused ja pakendi infolehed tuleb Euroopa Liidus ühtlustada.
English: Based on the data reviewed, the CHMP decided a harmonisation of the contraindications of Tavanic in patients hypersensitive (allergic) to levofloxacin, any other quinolone or any of the excipients, in patients with epilepsy, in patients with history of tendon disorders related to fluoroquinolone administration, in children or growing adolescents, during pregnancy and in breast-feeding women.
Estonian: Tuginedes läbivaadatud andmetele, otsustas inimravimite komitee ühtlustada Tavanici vastunäidustused ülitundlikkuse korral levofloksatsiini, teiste kinoloonide või mis tahes koostisainete suhtes, epilepsiaga patsientidel, patsientidel, kellel esineb anamneesis fluorokinoloonide manustamisega seotud kõõlusekahjustusi, lastel ja noorukitel, rasedatel ning imetavatel naistel.
English: Having harmonised the indications, the CHMP also harmonised the recommendations on the posology and frequency of administration of Tavanic, including the posology for acute exacerbations of chronic bronchitis and pyelonephritis.
Estonian: Pärast näidustuste ühtlustamist ühtlustas inimravimite komitee ka Tavanici annustamise ja manustamissageduse soovitused, sh annustamise kroonilise bronhiidi ägenemise ja püelonefriidi korral.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the product information for Tavanic in the European Union (EU).
Estonian: EMA inimravimite komitee järeldas, et Tavanici ravimiteave tuleb Euroopa Liidus ühtlustada.
English: This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.
Estonian: Tavanic on Euroopa Liidus heaks kiidetud riiklike menetluste kaudu, mille tõttu on ravimi näidustused, ravimi omaduste kokkuvõtted, märgistus ja pakendi infoleht Tavanici turustavates liikmesriikides erinevad.
English: • Tavanic 250 mg and 500 mg film-coated tablets are indicated in acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia and complicated skin and soft tissue infections only when other commonly used antibacterial agents are not recommended.
Estonian: • Tavanici 250 mg ja 500 mg õhukese polümeerkattega tabletid on näidustatud ägeda bakteriaalse sinusiidi, kroonilise bronhiidi ägenemise, keskkonnatekkelise kopsupõletiku ning naha ja antibakteriaalsed ained ei ole soovitatavad.
English: By doing this, it stops the bacteria that are causing an infection from growing and multiplying.
Estonian: See blokeerib bakterite DNA replikatsioonil osaleva ensüümi, millega peatab ravim infektsiooni põhjustavate bakterite kasvu ja paljunemise.
English: They are also indicated in pyelonephritis and complicated urinary tract infections (UTI), chronic bacterial prostatitis, uncomplicated cystitis and for the post-exposure prophylaxis and curative treatment of
Estonian: Samuti on tabletid näidustatud püelonefriidi ja kuseteede tüsistunud infektsioonide, kroonilise bakteriaalse prostatiidi, tüsistusteta tsüstiidi korral ning Siberi katku kopsuvormi kokkupuutejärgseks profülaktikaks ja raviks.
English: • Tavanic 5mg/ml solution for infusion is indicated in community-acquired pneumonia and complicated skin and soft tissue infections only when other commonly used antibacterials are not recommended.
Estonian: • Tavanic 5 mg/ml infusioonilahus on näidustatud keskkonnatekkelise kopsupõletiku ning naha ja antibakteriaalsed ained ei ole soovitatavad.
English: Tavanic was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Estonian: Inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste koordineerimisrühm nimetas Tavanici ühtlustamist vajavaks ravimiks.
English: Zaltrap aflibercept
Estonian: Zaltrap aflibertsept
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zaltrap on 1 February 2013.
Estonian: Euroopa Komisjon andis Zaltrapi müügiloa, mis kehtib kogu Euroopa Liidus, 1. veebruaril 2013.
English: What measures are being taken to ensure the safe and effective use of Zaltrap?
Estonian: Mis meetmed võetakse, et tagada Zaltrapi ohutu ja efektiivne kasutamine?
English: This cycle of treatment is repeated every two weeks, until the disease gets worse or the patient cannot tolerate the treatment.
Estonian: Sellist ravikuuri korratakse iga kahe nädala järel seni, kuni haigus süveneb või kuni patsient ravi enam ei talu.
English: What is Zaltrap and what is it used for?
Estonian: Mis on Zaltrap ja milleks seda kasutatakse?
English: The full EPAR for Zaltrap can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zaltrapi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Zaltrap
Estonian: Muu teave Zaltrapi kohta
English: Although medicines containing the same active substance are available for injection into the eye, Zaltrap must not be injected into the eye as it was not developed for such use and may cause local damage.
Estonian: Kuigi on olemas sama toimeainet sisaldavad silma süstitavad ravimid, ei tohi Zaltrapit süstida silma, sest seda ei ole selleks näidustuseks välja töötatud ja võib põhjustada paikseid kahjustusi.
English: Overall, the European Medicines Agency decided that Zaltrap's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Zaltrapi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Although Zaltrap is associated with significant side effects, which can be severe enough to force treatment to be stopped, the results of the large main study show that there is a small but clinically significant benefit in prolonging the life of treated patients in whom previous treatment failed.
Estonian: Kuigi Zaltrapi kasutamine on seotud oluliste kõrvalnähtudega, mis võivad olla piisavalt rasked, et ravi peab lõpetama, näitavad suure põhiuuringu tulemused, et ravil on väike, kuid kliiniliselt oluline kasulikkus elumuse pikendamisel patsientidel, kellel varasem ravi on ebaõnnestunud.
English: What are the risks associated with Zaltrap?
Estonian: Mis riskid Zaltrapiga kaasnevad?
English: Zaltrap is given as an infusion (drip) into the vein over one hour, at a dose of 4 mg per kilogram body weight.
Estonian: Zaltrapit manustatakse veeniinfusioonina (tilgutiga) ühe tunni jooksul annuses 4 mg kehamassi kilogrammi kohta.
English: Why is Zaltrap approved?
Estonian: Miks Zaltrap heaks kiideti?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zaltrap have been included in the summary of product characteristics and the package leaflet.
Estonian: Zaltrapi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The main measure of effectiveness was the average length of time that patients survived after treatment.
Estonian: Efektiivsuse põhinäitaja oli keskmine ravijärgne elumus (kui kaua patsiendid elasid pärast ravi).
English: It is not intended to provide practical advice on how to use Zaltrap.
Estonian: Hindamisaruandes ei anta Zaltrapi kasutamise praktilisi nõuandeid.
English: In this study, Zaltrap was more effective than placebo at increasing survival of patients: patients treated with Zaltrap plus FOLFIRI lived an average of 13.5 months, whereas patients treated with placebo and FOLFIRI lived an average of 12.1 months.
Estonian: Selles uuringus oli Zaltrap patsientide elumuse suurendamisel efektiivsem kui platseebo: Zaltrapit koos skeemiga FOLFIRI kasutanud patsiendid elasid keskmiselt 13,5 kuud ja platseebot koos skeemiga FOLFIRI kasutanud patsiendid keskmiselt 12,1 kuud.
English: This is then followed by the FOLFIRI treatment.
Estonian: Sellele järgneb ravi skeemi FOLFIRI järgi.
English: The medicine contains the active substance aflibercept.
Estonian: Ravim sisaldab toimeainena aflibertseptiini.
English: As a result, the cancer cells cannot develop their own blood supply and are starved of oxygen and nutrients, so helping to slow down the growth of tumours.
Estonian: Selle tulemusena ei teki vähirakkudel piisavat verevarustust ning need jäävad hapniku ja toitaineteta, mis aeglustab kasvaja kasvu.
English: Zaltrap is used with FOLFIRI, which is a treatment combining the medicines irinotecan, 5-fluorouracil, and folinic acid.
Estonian: Zaltrapit kasutatakse koos raviskeemiga FOLFIRI, mis kombineerib selliseid ravimeid nagu irinotekaan, 5-fluorouratsiil ja foliinhape.
English: The most common side effects with Zaltrap in combination with FOLFIRI (which may affect more than 20 patients in 100) are leucopenia and neutropenia (low levels of white cells in the blood, including the type that fight infections), diarrhoea, proteinuria (protein in the urine), increased blood levels of liver enzymes (aspartate and alanine transaminases), stomatitis (inflammation of the mouth), tiredness, thrombocytopenia (low blood platelet counts), hypertension (high blood pressure), weight loss, decreased appetite, epistaxis (nose bleeds), abdominal pain, dysphonia (speech disturbance), increases in creatinine in the blood (a marker of kidney problems), and headache.
Estonian: Zaltrapi ja FOLFIRI kombinatsiooni kõige sagedamad kõrvalnähud (võivad esineda rohkem kui 20 patsiendil 100st) on leukopeenia (leukotsüütide ehk vere valgeliblede vähesus), neutropeenia (neutrofiilide ehk teatud infektsioonivastaste valgeliblede vähesus), kõhulahtisus, proteinuuria (valkkusesus), maksaensüümide (aspartaadi ja alaniini aminotransferaas) sisalduse suurenemine veres, stomatiit (suulimaskesta põletik), väsimus, trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus), kõrge vererõhk, kaalulangus, isutus, ninaverejooks, kõhuvalu, düsfoonia (kähedus), vere kreatiniinisisalduse (neerukahjustuse näitaja) suurenemine ja peavalu.
English: For practical information about using Zaltrap, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Zaltrapi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Zaltrap can only be obtained with a prescription and treatment should be supervised by a doctor who is experienced in using cancer medicines.
Estonian: Zaltrap on retseptiravim ja ravi peab jälgima vähiravimite kasutamises kogenud arst.
English: By binding to VEGF and PlGF, aflibercept stops them having an effect.
Estonian: Aflibertsepti seondumine VEGF-i ja PIGF-iga peatab nende ainete toime.
English: Zaltrap is a cancer medicine used to treat adults with metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body) for whom treatment based on another medicine, oxaliplatin, has not worked or the cancer got worse.
Estonian: Zaltrap on vähiravim, mida kasutatakse metastaatilise kolorektaalvähiga (organismis mujale levinud jämesoolevähiga) täiskasvanud patsientide raviks, kellel varasem oksaliplatiinipõhine ravi ei ole toiminud või kelle vähk on süvenenud.
English: Zaltrap was investigated in one main study involving 1,226 adults with metastatic colorectal cancer that had not responded to oxaliplatin-based treatment.
Estonian: Zaltrapit on uuritud ühes põhiuuringus, kus osales 1226 oksaliplatiinipõhisele ravile mittereageerinud metastaatilise kolorektaalvähiga täiskasvanud patsienti.
English: For the full list of all side effects reported with Zaltrap, see the package leaflet.
Estonian: Zaltrapi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: For more information about treatment with Zaltrap, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zaltrapiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What benefits of Zaltrap have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Zaltrapi kasulikkus?
English: The most common effects that led to treatment being permanently stopped were problems with the circulation including hypertension, infections, tiredness, diarrhoea, dehydration, stomatitis, neutropenia, proteinuria, and pulmonary embolism (a clot in a blood vessel supplying the lungs).
Estonian: Kõige sagedamad kõrvalnähud, mille tõttu oli vaja ravi jäädavalt lõpetada, olid vereringeprobleemid, sealhulgas kõrge vererõhk, infektsioonid (nakkused), väsimus, kõhulahtisus, dehüdratsioon (veetustumine), stomatiit, neutropeenia, proteinuuria ja kopsuveresoonte emboolia (kopsuarteri tromb).
English: The active substance in Zaltrap, aflibercept, is a protein that attaches to vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF), substances that circulate in the blood and make blood vessels grow.
Estonian: Zaltrapi toimeaine aflibertsept on valk, mis seondub veres sisalduvate ainetega vaskulaarse endoteeli kasvufaktori (VEGF) ja platsenta kasvufaktoriga (PIGF).
English: This is a summary of the European public assessment report (EPAR) for Zaltrap.
Estonian: See on ravimi Zaltrap Euroopa avaliku hindamisaruande kokkuvõte.
English: Zaltrap was compared with placebo (a dummy treatment) when added to FOLFIRI.
Estonian: Zaltrapit võrreldi skeemile FOLFIRI lisatud platseeboga (näiva ravimiga).
English: How is Zaltrap used?
Estonian: Kuidas Zaltrapit kasutatakse?
English: How does Zaltrap work?
Estonian: Kuidas Zaltrap toimib?
English: Treatment should be discontinued, delayed, or the dose may have to be adjusted, in patients who develop certain side effects.
Estonian: Teatud kõrvalnähtude tekkimisel peab ravi katkestama või edasi lükkama või annust muutma.
English: For further details, see the package leaflet.
Estonian: Üksikasjalik teave on pakendi infolehel.
English: (Invented) nameStrength Pharmaceutical Form Route of AdministrationImmediate PackagingPack size
Estonian: Manustamistee Sisepakendi iseloomustus Pakendi suurus
English: 21 January 2013
Estonian: 21. jaanuar 2013
English: The European Commission issued a decision on this opinion on 21 January 2013.
Estonian: Euroopa Komisjon tegi sellel arvamusel põhineva otsuse 21. jaanuaril 2013.
English: After re-examination, the Committee confirmed these recommendations on 18 October 2012.
Estonian: Pärast taasläbivaatamist kinnitas inimravimite komitee 18. oktoobril 2012 antud soovitused.
English: What is tolperisone?
Estonian: Mis on tolperisoon?
English: The full changes made to the information to doctors and patients are detailed here.
Estonian: Muudetud teave arstidele ja patsientidele on siin.
English: Why were tolperisone-containing medicines reviewed?
Estonian: Miks tolperisooni sisaldavad ravimid läbi vaadati?